Abstract 141P
Background
The cultivation mode for tumor stem cells generally involves sorting. Fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS) are the main techniques for sorting CSCs. However, this is not the optimal solution. FACS is time-consuming, technically demanding, and yields a limited number of sorted cells. MACS, while operationally simple, can only sort one marker at a time. Conditional culture media require the addition of a large quantity of expensive growth factors. We established a dynamic suspension culture without additional sorting and cytokines to obtain cancer stem cell.
Methods
A dynamic suspension culture system without sorting and additional cytokines was used to obtain cancer stem cells. The immunostaining, RNA-seq, metabolomics and proteomics were performed to analyze the properties of cancer stem cells.
Results
The cancer stem cell was successfully cultivated from unconditionally dynamic suspension culture system. They exhibited the expression of specific cancer stem markers, such as upregulated CD44, CD133, ALDHA1, ABCB5 and decreased CD24.These cells possessed self-renewal capability and strong tumorigenicity. Meanwhile, their transcriptome, metabolism, proteins were reprogrammed. Drug metabolism cytochrome P450 and resistance to many drugs, such as platinum and methotrexate were activated. A metabolic switch from glycolysis to oxidative phosphorylation was founded in these cells. Importantly, actin cytoskeleton rearrangement and epithelial-mesenchymal transition were observed in these cells. The RNA-seq analyses show that signaling pathways, including HIF, Hippo and Wnt pathway were activated, resulting in the remodeling of cancer stem cell.
Conclusions
Independently sorting and the addition of cytokines, a dynamic suspension culture system can successfully generate cancer stem cells. These cells exhibited typical cancer stem cell properties, including reprogrammed transcriptome, metabolism, and protein levels. This unconditional dynamic suspension culture system offers an alternative method for cultivating cancer stem cells and presents a novel model for exploring their characteristics.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4P - Predicting triple-negative breast cancer molecular subtype from hematoxylin and eosin using deep neural networks
Presenter: Nicola Occelli
Session: Cocktail & Poster Display session
Resources:
Abstract
5P - Onconaut: A precision medicine platform for oncology therapies
Presenter: Altuna Akalin
Session: Cocktail & Poster Display session
Resources:
Abstract
6P - Diagnostic accuracy of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry slides: A systematic review and meta-analysis
Presenter: Daniel Arruda Navarro Albuquerque
Session: Cocktail & Poster Display session
Resources:
Abstract
8P - Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers
Presenter: Sofia Merajver
Session: Cocktail & Poster Display session
Resources:
Abstract
9P - Circulating tumor cells and circulating tumor DNA detection in colorectal cancer stage III patients receiving three or six months of adjuvant treatment
Presenter: Asimina Koulouridi
Session: Cocktail & Poster Display session
Resources:
Abstract
10P - Novel theranostic agents in non-metastatic Egyptian breast cancer patients: miR-96, miR-1275, miR-4317 and miR-744
Presenter: Ahmed Mokhtar
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - A prospective study to evaluate the prognostic implications and molecular mechanism of SLC40A1 gene in primary acute myeloid leukemia
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Prognostic value of PD-L1 expression and neutrophil-to-lymphocyte ratio to neoadjuvant chemo-immunotherapy in muscle-invasive urothelial carcinoma patients from the AURA trial
Presenter: Jeremy Blanc
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - Methylation of BRCA1 and RAD51C promoters determined by droplet digital PCR predicts homologous repair deficiency in patients with high-grade serous ovarian cancer: Results of the BOVARY-pilot study in paired FFPE and plasma samples and the ICL ovarian cohort
Presenter: Cassandra Michel
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - SLFN11 detection in patients with small cell lung cancer treated with lurbinectedin: A retrospective translational analysis
Presenter: Daniela Scattolin
Session: Cocktail & Poster Display session
Resources:
Abstract